Hypotensive Drugs

PreclinicalSmall molecule

TThird Affiliated Hospital, Sun Yat-Sen University

Hypotensive Drugs is one of 14 small molecule programs targeting Adenoma. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

AdenomaActive, not recruiting

AdenomaPreclinical

Active, not recruiting

Competition

Competitive Landscape

16 competitors in Adenoma

#DrugCompanyPhaseTrials

Dostinex

Pfizer

Approved

4 2

Orilissa

AbbVie

Approved

1 3

Nolvadex

Duragesic

Eflornithine Plus Sulindac

CCancer Prevention Pharmaceuticals, Inc.

Phase 3

1 6

Biaxin

AbbVie

Preclinical

1 7

Avandia

Jazz Pharmaceuticals

Preclinical

1 8

Ultram

WWim Janssens

Preclinical

1 9

Cortef

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

1 10

Drug Treatment

BBiosense Webster, Inc.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2030

Recruiting

Adenoma

NCT05991856

Clinical

Trials by Indication[1]

Adenoma1 trial

Multifaceted Comparison of Ultrasound-guided Ablation and Laparoscopic Adrenalectomy for Aldosterone-producing Adenoma

Recruiting·TThird Affiliated Hospital, Sun Yat-Sen University··NCT05991856·45 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Hypotensive Drugs. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Hypotensive Drugs compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Hypotensive Drugs. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Third Affiliated Hospital, Sun Yat-Sen University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: TThird Affiliated Hospital, Sun Yat-Sen University

Hypotensive Drugs

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2030

Trials by Indication[1]

Adenoma1 trial

References

Drug Info

Quick Facts

Related News